RecruitingPhase 3NCT05732272

Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment

Sponsor

University of Kansas Medical Center

Enrollment

500 participants

Start Date

Feb 28, 2023

Study Type

INTERVENTIONAL

Conditions

Smoking Cessation

Summary

This study will evaluate the efficacy of extended bupropion(6 months) versus standard bupropion treatment (7 weeks) among African American daily smokers.

Eligibility

Min Age: 18 Years

Inclusion Criteria7

African American
age >18 years
interested in quitting
smoked >1 cpd for >1 years
smoked on >25 days in the past month
willing to take 6 months of study medication and complete all visits
have a home address and functioning telephone number

Exclusion Criteria13

Consistent with contraindications for bupropion:
use of psychoactive medications
history of alcohol or substance abuse within the past year
binge drinking (>5 drinks on one occasion) >2 times in the past month
history of seizures or head trauma; history of bulimia or anorexia nervosa
pregnant (as measured by over the counter pregnancy test kit for women of child-bearing age only) or contemplating pregnancy; breast feeding
myocardial infarction in the past 2 months
reported use of opiates, cocaine, or stimulants
unstable diabetes
bupropion is a known inhibitor of the liver enzyme CYP2D6, so those taking drugs known to be higher metabolized by this enzyme (e.g., metoprolol, tamoxifen) will be excluded.
use of stop smoking medications (bupropion, varenicline, nicotine replacement, fluoxetine, clonidine, buspirone, or doxepin) in the past 30 days
planning to move from the Kansas City area in the next year
other smoker in household enrolled in the study.